This is a snippet of the transcript, sign up to read more.
We use Refinitiv as well. We use Refinitiv for adverse media, PEPs, and sanction screening. They can do more than what we are paying for right now, but they lack the most important feature that Moody's has, which is access to pull out data for us. If you are providing KYB solutions, this is important.
This is a snippet of the transcript, sign up to read more.
This KYB company I mentioned at the beginning was offering the same needs. They were doing a bit better. I don't remember the exact pricing from two years ago, but when we compared, it was more beneficial for the company because they also focused more on Europe, and the documents were available immediately upon request. They were not focusing globally like Moody's, but more locally. They were from the UK when they started and pulled out documentation much quicker. Sometimes with Moody's, you need to wait for the documents.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.